What is Stryker?
Medical technology company with ~$25B of 2025 revenue and enterprise healthcare scale.
- Category
- Medical technology
- Headquarters
- Portage, MI
- Founded
- 1941
- Employees
- 60,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: SYK; ~$150B market cap
What is Stryker?
Stryker is a public medical technology company headquartered in Portage, MI. It reported ~$25B of 2025 revenue and operates at global enterprise scale.
Stryker operates in medical technology with a portfolio spanning MedSurg and Neurotechnology, and Orthopaedics. The company reported ~$25B of 2025 revenue, employs about 60,000+, and trades as NYSE: SYK. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, Stryker is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, Stryker is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does Stryker offer?
Stryker offers healthcare products and services across MedSurg and Neurotechnology, and Orthopaedics.
- Orthopaedic implants· Orthopaedics
- Mako robotic-arm surgery· Robotics
- Neurotechnology· Neurotechnology
- Endoscopy and communications· MedSurg
- Emergency care· MedSurg
- Surgical instruments· MedSurg
- Spine· Orthopaedics
How does Stryker make money?
Stryker sells capital equipment, implants, instruments, disposables, service, and software-enabled surgical workflows to hospitals, ambulatory surgery centers, surgeons, and health systems.
Stryker sells capital equipment, implants, instruments, disposables, service, and software-enabled surgical workflows to hospitals, ambulatory surgery centers, surgeons, and health systems. In 2025, that model produced ~$25B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is contract-, procedure-, implant-, capital-equipment-, service-, and group-purchasing driven; Mako systems, implants, disposables, and support are negotiated by account and procedure economics rather than public tiers. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads Stryker?
Stryker is led by Kevin A. Lobo, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Kevin A. LoboChair and Chief Executive OfficerCEO since 2012Long-tenured CEO leading Stryker's medtech growth and acquisitions.
- Preston WellsVice President and Chief Financial OfficerCFO in 2026Finance leader listed on Stryker's 2026 management page.
- Spencer StilesPresident and Chief Operating OfficerSenior executive leadershipOperations and commercial executive across major Stryker businesses.
- Debra KingVice President, Chief Digital and Information OfficerSenior executive leadershipKey technology, data, and enterprise systems leader.
How do you contact Stryker's leadership?
Stryker publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investor.relations@stryker.com) or official contact forms rather than guessed personal addresses.
investor.relations@stryker.com is a public investor/contact route; personal executive email format not verifiedHow much funding has Stryker raised?
Stryker is a mature public company, not a venture-backed startup. It trades as NYSE: SYK, had an approximate ~$150B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
Stryker's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1941, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported ~$25B of 2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: Stryker has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did Stryker get here?
Stryker grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 1941Company foundedOrthopedic surgeon Homer Stryker starts the company.
- 1979Stryker goes publicThe company lists publicly and scales medical-device manufacturing.
- 2013Mako acquiredStryker moves deeper into robotic orthopedic surgery.
- 2020Wright Medical acquiredStryker expands extremities and biologics.
- 2025Strong medtech growthStryker reports double-digit 2025 net sales growth.
- 2026CFO transition reflectedPreston Wells is listed as CFO on Stryker's management page.
Who are Stryker's competitors?
Stryker competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- Johnson & Johnson MedTechCompetes in orthopaedics, surgery, spine, and interventional medical devices.
- Zimmer BiometOrthopaedic reconstruction and surgical robotics competitor.
- MedtronicLarge medtech competitor across surgery, neuro, spine, and capital equipment.
- Smith+NephewOrthopaedics, sports medicine, wound, and surgical-device competitor.
- Boston ScientificInterventional-medtech competitor in overlapping hospital buying centers.
Stryker — frequently asked questions
